TG Therapeutics Inc. Common Stock (TGTX)

FairStock Score: 65/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Looking at TG Therapeutics, I see a commercial-stage biotech whose revenue is moving in the right direction. In fiscal 2025, ended 2025-12-31, revenue was $616.3M and net income was $447.2M, up from $329.0M revenue and $23.4M net income in fiscal 2024. But the latest quarters show how lumpy this business can be: in fiscal Q2 2026, ended 2026-06-30, revenue rose to $240.3M, yet net income was only $7.8M, or $0.05 diluted EPS. That followed fiscal Q1 2026 net income of $19.8M on $204.9M revenue. The large fiscal Q3 2025 profit of $390.9M flattered trailing results, so I would not treat FairStock's P/E of 19.83 on the 2026-10-13 close of $54.34 as a durable bargain. The balance sheet has debt, with D/E of 1.25, and while the Altman Z-Score of 4.75 and Piotroski F-Score of 6/9 are not alarming, ROCE is only 7.28% and free cash flow is just $17.4M, a 0.2% FCF yield. That is thin for an $8.3B market cap. The company depends heavily on one commercial product, BRIUMVI, which gives it growth but not a wide moat; competition and reimbursement could pressure pricing. Valuation is demanding: P/B is 13.22, EV/EBITDA is 61.62, and the Graham Number is $15.61 versus the $54.34 close, leaving no margin of safety. FairStock scores it 65/100 and classifies it as a TURNAROUND, which fits. I would want evidence that revenue growth converts into sustainable cash earnings before calling this a bargain.

In plain English: TG Therapeutics is a drug company that sells BRIUMVI, a treatment for relapsing multiple sclerosis. Sales are growing, but profits are small and uneven, and the stock price looks high compared with the company's cash generation and asset value. It may be a turnaround, but it is not obviously cheap.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer